STOCK TITAN

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

ProPhase Labs Inc. (NASDAQ: PRPH) has announced it will present its first quarter 2025 financial results in a virtual conference call on May 20, 2025, at 10:00 am EDT.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

ProPhase Labs Inc. (NASDAQ: PRPH) has announced it will present its first quarter 2025 financial results in a virtual conference call on May 20, 2025, at 10:00 am EDT. The call, hosted by Renmark Financial, will feature CEO Ted Karkus providing updates on key initiatives, including:

- The planned sale of subsidiary Nebula Genomics
- Crown Medical Collections' initiative to recover tens of millions in accounts receivable

A press release with detailed results will be issued before the call. The company, a next-generation biotech, genomics and consumer products company, focuses on Whole Genome Sequencing solutions, diagnostic development including early esophageal cancer detection, and direct-to-consumer marketing for OTC dietary supplements.

Loading...
Loading translation...
Argus Session date unavailable
+3.98% session move Open Argus
Details

News Market Reaction – PRPH

The recorded move for PRPH in the trading session of this news was +3.98%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company’s wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable.

A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s investor website.

REGISTER HERE: https://www.renmarkfinancial.com/events/first-quarter-2025-results-virtual-conference-call-nasdaq-prph-b--whRs2Li

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ProPhase Labs Inc.

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com

Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com

Retail Investor Relations Contact:
Renmark Financial Communications Inc.
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will PRPH release its Q1 2025 earnings?

ProPhase Labs (PRPH) will release its Q1 2025 earnings via a press release before its virtual conference call scheduled for May 20, 2025, at 10:00 am EDT.

What key updates will be discussed in ProPhase Labs' Q1 2025 earnings call?

CEO Ted Karkus will discuss two main initiatives: the planned sale of subsidiary Nebula Genomics and Crown Medical Collections' efforts to collect tens of millions in accounts receivable.

How can investors participate in PRPH's Q1 2025 earnings call?

Investors can participate by registering through Renmark Financial's website. The event requires the latest version of Google Chrome for optimal connectivity.

What are ProPhase Labs' main business segments?

ProPhase Labs focuses on Whole Genome Sequencing solutions, diagnostic development (including early esophageal cancer detection), and direct-to-consumer marketing for OTC dietary supplements.

Keep reading